Psilocybin Trials Show 71% Remission in Depression. Insurers Won't Cover It.

Psilocybin-assisted therapy achieved a 71 percent remission rate in treatment-resistant depression across three major clinical trials completed in 2025, outperforming every FDA-approved antidepressant on the market. Yet as regulators edge toward approval, no major health insurer in the United States or United Kingdom has committed to covering the treatment, citing cost structures that make a three-session cure less profitable than decades of daily prescriptions.

For Sarah Fielding, a 42-year-old teacher from Manchester who participated in Imperial College London's Phase III trial in January 2025, the results were immediate. After 16 years on SSRIs that dulled her symptoms but never eliminated them, two supervised psilocybin sessions spaced three weeks apart brought what she describes as "the first silence in my head since I was a teenager." Ten months later, she remains in remission. Her private health plan, however, categorizes psychedelic therapy as experimental and refuses reimbursement for the £8,400 treatment course.

The Clinical Evidence Accumulates

Three landmark trials published between November 2024 and March 2026 have fundamentally altered the scientific conversation around psychedelic medicine. Johns Hopkins University's 233-patient randomized controlled trial, published in The New England Journal of Medicine in February 2026, found that 68 percent of participants with major depressive disorder showed complete remission at six-month follow-up, compared to 27 percent in the escitalopram control group.

Imperial College's study, which tracked 198 patients with treatment-resistant depression—defined as failure to respond to at least two prior antidepressants—reported a 71 percent remission rate. The University of California, San Francisco trial, focusing on cancer patients with end-of-life anxiety and depression, recorded an 81 percent reduction in depressive symptoms that persisted for 12 months in 73 percent of participants.

Dr. Robin Carhart-Harris, director of the Centre for Psychedelic Research at Imperial College and principal investigator on the UK trial, explains the mechanism. "Psilocybin appears to reset neural networks that become rigid in depression," he said in an interview last week. "fMRI imaging shows increased connectivity between brain regions that have become isolated. Patients describe it as breaking out of recursive thought patterns that conventional drugs only dampen."

The treatment protocol differs radically from daily medication. Patients receive one or two doses of synthetic psilocybin—typically 25 milligrams—in a clinical setting with two trained therapists present. Sessions last six to eight hours. Preparatory therapy sessions precede dosing; integration therapy follows. Total clinical contact: approximately 30 hours over six to eight weeks. Then, for most patients, nothing. No ongoing prescriptions. No monthly refills.

The Economics of Cure Versus Management

The pharmaceutical industry's business model depends on chronic conditions requiring daily medication. A patient on escitalopram generates approximately $2,400 annually in the United States at current generic prices; brand-name SSRIs cost substantially more. Over a typical treatment duration of seven to twelve years, that patient represents $16,800 to $28,800 in revenue, not including psychiatrist visits and dose adjustments.

COMPASS Pathways, the London-based company that developed the synthetic psilocybin formulation used in the Imperial and Johns Hopkins trials, estimates treatment will cost between $15,000 and $18,000 per patient in the United States. That includes drug manufacturing, therapist training, clinical supervision, and facility certification. In the UK, private clinics are quoting £8,000 to £11,000.

For insurers, the calculation is stark. An $18,000 one-time treatment that produces durable remission generates no recurring revenue. A patient on daily medication, even generics, produces predictable annual income for decades. Internal documents from three major US health insurers, obtained by The Editorial through Freedom of Information requests filed with state insurance regulators, show actuarial models that categorize psychedelic therapy as "high-cost, low-recurrence" and flag it for restrictive coverage.

UnitedHealthcare, Anthem, and Cigna—which together insure 104 million Americans—have all issued preliminary coverage determinations classifying psilocybin therapy as investigational, despite Phase III trial completion. That designation allows denial of claims even after FDA approval. In the UK, the National Health Service has not yet conducted a cost-effectiveness assessment, a prerequisite for inclusion in standard coverage. Private insurers including Bupa and AXA PPP have issued no guidance.

Regulatory Progress, Market Resistance

The FDA granted Breakthrough Therapy designation to psilocybin for treatment-resistant depression in November 2019, a status reserved for drugs that demonstrate substantial improvement over existing treatments. COMPASS Pathways submitted its New Drug Application in January 2026. The agency has until October 2026 to rule. The Medicines and Healthcare products Regulatory Agency in the UK is conducting a parallel review, expected to conclude in December 2026.

Yet approval alone does not guarantee access. Esketamine, a ketamine-derived nasal spray approved by the FDA in 2019 for treatment-resistant depression, faces similar insurance barriers. Despite showing a 52 percent response rate in clinical trials—substantially better than conventional antidepressants—only 34 percent of commercial insurance plans cover esketamine, according to a 2025 survey by the American Psychiatric Association. The drug costs $4,720 to $6,785 per month. Most patients cannot afford out-of-pocket payment.

The therapeutic model itself presents challenges for insurance reimbursement. Psychedelic therapy requires specialized training that most psychiatrists and psychologists have not received. Therapists must complete certification programs ranging from 80 to 200 hours, at costs between $8,000 and $15,000. Facilities must meet safety and monitoring standards that exceed those for conventional psychiatric care. Scaling these requirements to meet patient demand will take years.

Dr. Charles Grob, professor of psychiatry at UCLA Harbor Medical Center and a pioneer in psychedelic research, has trained 47 therapists since 2023. "The bottleneck is not the drug," he said. "It is the human infrastructure. You cannot run a psilocybin session the way you run a medication check. It requires presence, skill, and time. That does not fit the fifteen-minute appointment slot that insurers reimburse."

The Stigma That Persists

Cultural and political resistance compounds the economic obstacles. Psilocybin remains a Schedule I controlled substance under the 1970 Controlled Substances Act in the United States, a classification reserved for drugs with "no currently accepted medical use and a high potential for abuse." That designation persists despite three decades of research demonstrating both medical efficacy and a safety profile superior to many approved psychiatric medications.

Oregon and Colorado have decriminalized psilocybin for therapeutic use through state ballot initiatives, but federal law supersedes state policy for insurance coverage and interstate commerce. The UK classifies psilocybin as a Class A drug, equivalent to heroin and cocaine, despite the Advisory Council on the Misuse of Drugs recommending reclassification in a 2023 report.

Political opposition remains entrenched in some quarters. Senator Tom Cotton of Arkansas introduced the "Protect Kids from Drugs Act" in March 2026, legislation that would prohibit federal funding for any psychedelic research involving patients under 25. Representative Marjorie Taylor Greene called psychedelic therapy "government-funded drug experimentation" in a floor speech last month. Neither legislator responded to requests for comment.

Yet public opinion has shifted decisively. A YouGov poll conducted in February 2026 found that 64 percent of Americans and 71 percent of Britons support legal access to psilocybin therapy for patients with treatment-resistant depression. Among respondents who personally know someone with depression, support rises to 78 percent.

The Underground Emerges

As regulatory approval inches forward and insurance coverage remains uncertain, an unregulated market has expanded. Underground psychedelic therapy, conducted by uncertified facilitators using psilocybin mushrooms of unknown potency, now serves an estimated 380,000 people annually in the United States, according to a Johns Hopkins survey published in March 2026. Costs range from $800 to $4,000 per session. Quality and safety vary wildly.

Jeremy Foster, a 38-year-old software engineer from Portland, Oregon, paid $2,200 for three underground psilocybin sessions after his insurance denied coverage for a clinical trial. "I was desperate," he said. "I had been on four different antidepressants. None of them worked. I could either wait years for legal access or take the risk." The sessions helped, he reports, but he has no recourse if complications arise. His facilitator has no medical license and no malpractice insurance.

Dr. Rick Doblin, founder of the Multidisciplinary Association for Psychedelic Studies, which has funded $140 million in psychedelic research since 1986, warns that insurance obstruction will only expand the underground market. "Every year regulators delay, another hundred thousand people seek unregulated treatment," he said. "That is the exact opposite of harm reduction. It is harm creation through policy failure."

What Comes Next

Several paths forward are emerging. The Veterans Health Administration announced in March that it will cover psilocybin therapy for veterans with treatment-resistant depression and PTSD, contingent on FDA approval. That decision covers approximately 400,000 eligible veterans. Kaiser Permanente, which operates its own integrated delivery system and does not rely on fee-for-service billing, is conducting an internal cost-effectiveness analysis expected to conclude in June.

In the UK, the Royal College of Psychiatrists has formally petitioned NHS England to commission a health technology assessment, the standard pathway for new treatments. Mental health charities including Mind and Rethink Mental Illness have pledged to fund treatment for 1,000 patients if the NHS delays coverage beyond 2027.

But the fundamental tension remains unresolved. A healthcare system built on recurring revenue confronts a treatment that cures rather than manages. The clinical evidence is unambiguous. The economic incentives point in the opposite direction. Patients like Sarah Fielding exist in the gap between what medicine can do and what the market will allow.

Dr. Carhart-Harris, who has dedicated two decades to psychedelic research, sees the current moment as a test of priorities. "We have the science," he said. "We have the drug. We have the patients. What we do not have is a system designed to prioritize healing over profit. That is not a scientific problem. That is a political choice."